Simple urine test may spot kidney trouble early in kids with cancer
NCT ID NCT02822404
First seen Apr 02, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This study looked at whether a substance called cystatin C, measured in urine and blood, can detect kidney damage from chemotherapy drugs cisplatin and ifosfamide in children. Researchers followed 42 children and compared cystatin C levels to standard kidney tests. The goal was to find a simpler, less burdensome way to monitor kidney health during cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Toulouse
Toulouse, 31059, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If cystatin C proves reliable, it could offer a simpler, less invasive way to monitor kidney health in children undergoing chemotherapy.
What could go wrong
This is a small, completed observational study. The marker may not be accurate enough to replace current tests, and results may not apply to all children or treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.